Stephanie E Combs

List of Publications by Year
in descending order

320 papers	14,147 citations	18887 64 h-index	37326 100 g-index
341 all docs	341 docs citations	341 times ranked	15157 citing authors

#	Article	IF	Citations
1	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
2	Functional Network Connectivity Reveals the Brain Functional Alterations in Breast Cancer Survivors. Journal of Clinical Medicine, 2022, 11, 617.	1.0	5
3	Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy. Cancers, 2022, 14, 684.	1.7	2
4	Potential Molecular Biomarkers of Central Nervous System Damage in Breast Cancer Survivors. Journal of Clinical Medicine, 2022, 11, 1215.	1.0	5
5	Adhesion Molecules ICAM-1 and PECAM-1 as Potential Biomarkers of Central Nervous System Damage in Women Breast Cancer Survivors. Pathophysiology, 2022, 29, 52-65.	1.0	7
6	Heat management of a compact xâ€ray source for microbeam radiotherapy and FLASH treatments. Medical Physics, 2022, , .	1.6	4
7	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€“ Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
8	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
9	Commentary: Fractionated Proton Beam Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery, 2022, 91, e11-e12.	0.6	1
10	Oligometastasis in breast cancerâ€"current status and treatment options from aÂradiation oncology perspective. Strahlentherapie Und Onkologie, 2022, 198, 601-611.	1.0	11
11	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 2022, 14, 3031.	1.7	2
12	ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiotherapy and Oncology, 2021, 156, 80-94.	0.3	41
13	Web-Based Patient Self-Reported Outcome After Radiotherapy in Adolescents and Young Adults With Cancer: Survey on Acceptance of Digital Tools. JMIR MHealth and UHealth, 2021, 9, e19727.	1.8	4
14	Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. Radiotherapy and Oncology, 2021, 159, 265-276.	0.3	9
15	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
16	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiation Oncology, 2021, 16, 141.	1.2	9
17	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	1.0	16
18	Surgical Management of Jugular Foramen Schwannomas. Cancers, 2021, 13, 4218.	1.7	8

#	Article	IF	Citations
19	The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases. Cancers, 2021, 13, 70.	1.7	12
20	Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1391-1399.	3.3	15
21	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 15625.	1.6	34
22	Radiosensitization by Kinase Inhibition Revealed by Phosphoproteomic Analysis of Pancreatic Cancer Cells. Molecular and Cellular Proteomics, 2020, 19, 1649-1663.	2.5	7
23	Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature. BMC Cancer, 2020, 20, 1060.	1.1	10
24	Targeted Natural Killer Cellâ€“Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clinical Cancer Research, 2020, 26, 5368-5379.	3.2	42
25	MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression. Cancers, 2020, 12, 3760.	1.7	8
26	The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. Cancers, 2020, 12, 3703.	1.7	13
27	Is local radiotherapy a viable option for patients with an opening of the ventricles during surgical resection of brain metastases?. Radiation Oncology, 2020, 15, 276.	1.2	2
28	Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases. JAMA Oncology, 2020, 6, 1901.	3.4	47
29	The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme. Cancers, 2020, 12, 1099.	1.7	26
30	Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas. Neuro-Oncology, 2020, 22, 928-935.	0.6	62
31	Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO). BMC Cancer, 2020, 20, 442.	1.1	5
32	A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. Radiation Oncology, 2020, 15, 97.	1.2	15
33	Clinical microbeam radiation therapy with a compact source: specifications of the line-focus X-ray tube. Physics and Imaging in Radiation Oncology, 2020, 14, 74-81.	1.2	7
34	Predicting Glioblastoma Recurrence from Preoperative MR Scans Using Fractional-Anisotropy Maps with Free-Water Suppression. Cancers, 2020, 12, 728.	1.7	23
35	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiation Oncology, 2020, 15, 74.	1.2	50
36	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10

#	Article	IF	Citations
37	Stereotactic irradiation of the resection cavity after surgical resection of brain metastases â€“ when is the right timing?. Acta OncolÃ³gica, 2019, 58, 1714-1719.	0.8	11
38	Deep learning derived tumor infiltration maps for personalized target definition in Glioblastoma radiotherapy. Radiotherapy and Oncology, 2019, 138, 166-172.	0.3	28
39	A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers. Current Treatment Options in Oncology, 2019, 20, 71.	1.3	19
40	Digital biomarkers: Importance of patient stratification for re-irradiation of glioma patients â€“ Review of latest developments regarding scoring assessment. Physica Medica, 2019, 67, 20-26.	0.4	2
41	Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. PLoS ONE, 2019, 14, e0221502.	1.1	13
42	Re-irradiation in elderly patients with glioblastoma: a single institution experience. Journal of Neuro-Oncology, 2019, 142, 327-335.	1.4	11
43	Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas â€“ a single center experience. Radiation Oncology, 2019, 14, 2.	1.2	14
44	Application of presurgical navigated transcranial magnetic stimulation motor mapping for adjuvant radiotherapy planning in patients with high-grade gliomas. Radiotherapy and Oncology, 2019, 138, 30-37.	0.3	15
45	Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers, 2019, 11, 709.	1.7	32
46	Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy â€“ potential markers for predicting breast cancer recurrence?. Radiation Oncology, 2019, 14, 78.	1.2	40
47	Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2019, 14, 66.	1.2	9
48	Personalized Radiotherapy Design for Glioblastoma: Integrating Mathematical Tumor Models, Multimodal Scans, and Bayesian Inference. IEEE Transactions on Medical Imaging, 2019, 38, 1875-1884.	5.4	96
49	CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy. Radiotherapy and Oncology, 2019, 135, 187-196.	0.3	57
50	Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers, 2019, 11, 1655.	1.7	42
51	Neuroimaging for Radiation Therapy of Brain Tumors. Topics in Magnetic Resonance Imaging, 2019, 28, 63-71.	0.7	9
52	Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers, 2019, 11, 1884.	1.7	6
53	The Role of Particle Therapy for the Treatment of Skull Base Tumors and Tumors of the Central Nervous System (CNS). Topics in Magnetic Resonance Imaging, 2019, 28, 49-61.	0.7	1
54	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. Clinical Cancer Research, 2019, 25, 1505-1516.	3.2	67

#	Article	IF	Citations
55	Combining multimodal imaging and treatment features improves machine learningâ€based prognostic assessment in patients with glioblastoma multiforme. Cancer Medicine, 2019, 8, 128-136.	1.3	43
56	Cavity volume changes after surgery of aÂbrain metastasisâ€"consequences for stereotactic radiation therapy. Strahlentherapie Und Onkologie, 2019, 195, 207-217.	1.0	26
57	PET imaging in patients with brain metastasisâ€"report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	0.6	139
58	Radiation Therapy in Meningiomas. , 2019, , 1-12.		0
59	The algorithms of adjuvant therapy in gliomas and their effect on survival. Journal of Neurosurgical Sciences, 2019, 63, 179-186.	0.3	5
60	Moving Second Courses of Radiotherapy Forward. Neurosurgery, 2018, 83, 1241-1248.	0.6	14
61	Reâ€irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic scoreâ€"report of the Radiation Oncology Group (<scp>ROG</scp>) of the German Cancer Consortium (<scp>DKTK</scp>). Cancer Medicine, 2018, 7, 1742-1749.	1.3	34
62	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiotherapy and Oncology, 2018, 127, 121-127.	0.3	37
63	Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. Strahlentherapie Und Onkologie, 2018, 194, 580-590.	1.0	36
64	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
65	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
66	Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning. Radiation Oncology, 2018, 13, 54.	1.2	37
67	Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. Radiation Oncology, 2018, 13, 58.	1.2	25
68	Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Medicine, 2018, 7, 2319-2327.	1.3	27
69	Radiomics in radiooncology â€“ Challenging the medical physicist. Physica Medica, 2018, 48, 27-36.	0.4	71
70	Clinical outcome after high-precision radiotherapy for skull base meningiomas: Pooled data from three large German centers for radiation oncology. Radiotherapy and Oncology, 2018, 127, 274-279.	0.3	25
71	Retrospective Analysis of Radiological Recurrence Patterns in Glioblastoma, Their Prognostic Value And Association to Postoperative Infarct Volume. Scientific Reports, 2018, 8, 4561.	1.6	48
72	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410.	0.6	56

#	Article	IF	Citations
73	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24
74	Essential role of radiation therapy for the treatment of pancreatic cancer. Strahlentherapie Und Onkologie, 2018, 194, 185-195.	1.0	21
75	Perioperative chemotherapy vs. neoadjuvant chemoradiation inÂgastroesophageal junction adenocarcinoma. Strahlentherapie Und Onkologie, 2018, 194, 125-135.	1.0	13
76	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
77	Predicting brain tumor regrowth in relation to motor areas by functional brain mapping. Neuro-Oncology Practice, 2018, 5, 82-95.	1.0	4
78	Human Glioma Migration and Infiltration Properties as a Target for Personalized Radiation Medicine. Cancers, 2018, 10, 456.	1.7	43
79	Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. Cancers, 2018, 10, 401.	1.7	41
80	The Role of Navigated Transcranial Magnetic Stimulation Motor Mapping in Adjuvant Radiotherapy Planning in Patients With Supratentorial Brain Metastases. Frontiers in Oncology, 2018, 8, 424.	1.3	18
81	Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2018, 28, 309-320.	1.0	22
82	Clinical Rationale and Indications for Particle Therapy. Progress in Tumor Research, 2018, , 89-104.	0.1	4
83	Modern Techniques of Radiation Therapy in the Treatment of Brain Tumors and Tumors of the Skull Base. Neurology International Open, 2018, 2, E97-E107.	0.4	0
84	Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data. BMC Cancer, 2018, 18, 760.	1.1	13
85	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	1.2	34
86	Proton and Carbon Ion Therapy of Intracranial Gliomas. Progress in Neurological Surgery, 2018, 32, 57-65.	1.3	7
87	MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. Journal of Translational Medicine, 2018, 16, 109.	1.8	34
88	Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma â€“ the GlioCave study (NOA 17 â€“ ARO 2016/3 â€“ DKTK ROG trial). BMC Cancer, 2018, 18, 15.	1.1	22
89	Evaluation of the tumor movement and the reproducibility of two different immobilization setups for image-guided stereotactic body radiotherapy of liver tumors. Radiation Oncology, 2018, 13, 15.	1.2	3
90	Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Medicine, 2018, 7, 2350-2359.	1.3	15

#	Article	IF	Citations
91	Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma. Radiation Oncology, 2018, 13, 86.	1.2	35
92	Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2018, 13, 139.	1.2	23
93	Mobile App Delivery of the EORTC QLQ-C30 Questionnaire to Assess Health-Related Quality of Life in Oncological Patients: Usability Study. JMIR MHealth and UHealth, 2018, 6, e45.	1.8	19
94	Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study). JMIR Research Protocols, 2018, 7, e178.	0.5	23
95	Vestibular Schwannoma. , 2018, , 51-62.		0
96	Validation of an established prognostic score after re-irradiation of recurrent glioma. Acta OncolÃ³gica, 2017, 56, 422-426.	0.8	36
97	Volumetric response of intracranial meningioma after photon or particle irradiation. Acta OncolÃ³gica, 2017, 56, 431-437.	0.8	14
98	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	0.6	381
99	Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients. Strahlentherapie Und Onkologie, 2017, 193, 648-655.	1.0	25
100	Heart-sparing radiotherapy in patients with breast cancer: What are the techniques used in the clinical routine?. Medical Dosimetry, 2017, 42, 197-202.	0.4	16
101	Radiolucent Carbon Fiberâ€“Reinforced Pedicle Screws for Treatment of Spinal Tumors: Advantages for Radiation Planning and Follow-Up Imaging. World Neurosurgery, 2017, 105, 294-301.	0.7	93
102	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
103	Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience. Radiation Oncology, 2017, 12, 77.	1.2	4
104	Re-irradiation after gross total resection of recurrent glioblastoma. Strahlentherapie Und Onkologie, 2017, 193, 897-909.	1.0	30
105	High-precision radiotherapy for meningiomas. Strahlentherapie Und Onkologie, 2017, 193, 921-930.	1.0	22
106	Does Proton Therapy Have a Future in CNS Tumors?. Current Treatment Options in Neurology, 2017, 19, 12.	0.7	18
107	⁶⁸Gaâ€PSMAâ€PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate, 2017, 77, 920-927.	1.2	89
108	Sequential proton boost after standard chemoradiation for high-grade glioma. Radiotherapy and Oncology, 2017, 125, 266-272.	0.3	20

#	Article	IF	Citations
109	Interobserver variability of patient positioning using four different CT datasets for image registration in lung stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 831-839.	1.0	4
110	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16
111	â€œRadio-oncomicsâ€• Strahlentherapie Und Onkologie, 2017, 193, 767-779.	1.0	57
112	Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer, 2017, 17, 361.	1.1	67
113	Planning strategies for inter-fractional robustness in pancreatic patients treated with scanned carbon therapy. Radiation Oncology, 2017, 12, 94.	1.2	19
114	Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma. Strahlentherapie Und Onkologie, 2017, 193, 192-199.	1.0	26
115	Expert consensus on re-irradiation for recurrent glioma. Radiation Oncology, 2017, 12, 194.	1.2	32
116	Modern Imaging in Neurooncology. Neurology International Open, 2017, 01, E160-E170.	0.4	0
117	Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Frontiers in Oncology, 2017, 7, 35.	1.3	7
118	mHealth and Application Technology Supporting Clinical Trials: Todayâ€™s Limitations and Future Perspective of smartRCTs. Frontiers in Oncology, 2017, 7, 37.	1.3	16
119	Tangential Field Radiotherapy for Breast Cancerâ€”The Dose to the Heart and Heart Subvolumes: What Structures Must Be Contoured in Future Clinical Trials?. Frontiers in Oncology, 2017, 7, 130.	1.3	26
120	Comparative Analysis of Efficacy, Toxicity, and Patient-Reported Outcomes in Rectal Cancer Patients Undergoing Preoperative 3D Conformal Radiotherapy or VMAT. Frontiers in Oncology, 2017, 7, 225.	1.3	9
121	Use of Multicenter Data in a Large Cancer Registry for Evaluation of Outcome and Implementation of Novel Concepts. Frontiers in Oncology, 2017, 7, 234.	1.3	3
122	Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma. PLoS ONE, 2017, 12, e0180457.	1.1	32
123	Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. PLoS ONE, 2017, 12, e0180940.	1.1	21
124	Are heart toxicities in breast cancer patients important for radiation oncologists? A practice pattern survey in German speaking countries. BMC Cancer, 2017, 17, 563.	1.1	8
125	Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2017, 12, 182.	1.2	20
126	First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas. Radiation Oncology, 2017, 12, 169.	1.2	12

#	Article	IF	Citations
127	Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?. Radiation Oncology, 2017, 12, 203.	1.2	9
128	Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. JMIR MHealth and UHealth, 2017, 5, e81.	1.8	109
129	Protons, Photons, and the Prostate â€“ Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer?. Frontiers in Oncology, 2016, 6, 8.	1.3	13
130	Review of Developments in Electronic, Clinical Data Collection, and Documentation Systems over the Last Decade â€“ Are We Ready for Big Data in Routine Health Care?. Frontiers in Oncology, 2016, 6, 75.	1.3	14
131	Stress Response Leading to Resistance in Glioblastomaâ€”The Need for Innovative Radiotherapy (iRT) Concepts. Cancers, 2016, 8, 15.	1.7	22
132	Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiation Oncology, 2016, 11, 73.	1.2	79
133	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
134	Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging. International Journal of Hyperthermia, 2016, 32, 455-463.	1.1	14
135	HFSRT of the resection cavity in patients with brain metastases. Strahlentherapie Und Onkologie, 2016, 192, 368-376.	1.0	39
136	Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3DÂconformal radiotherapy or VMAT. Strahlentherapie Und Onkologie, 2016, 192, 722-729.	1.0	27
137	Registration uncertainties between 3D cone beam computed tomography and different reference CT datasets in lung stereotactic body radiation therapy. Radiation Oncology, 2016, 11, 142.	1.2	11
138	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
139	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer, 2016, 138, 171-181.	2.3	184
140	Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. Acta OncolÃ³gica, 2016, 55, 886-891.	0.8	16
141	Optic toxicity in radiation treatment of meningioma: a retrospective study in 213 patients. Journal of Neuro-Oncology, 2016, 127, 597-606.	1.4	20
142	Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging. Strahlentherapie Und Onkologie, 2016, 192, 209-215.	1.0	13
143	Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiotherapy and Oncology, 2016, 118, 176-180.	0.3	35
144	Is a modification of the radiotherapeutic target volume necessary after resection of glioblastomas with opening of the ventricles?. Journal of Neuro-Oncology, 2016, 127, 581-587.	1.4	5

#	Article	IF	Citations
145	ESTRO-ACROP guideline â€œtarget delineation of glioblastomasâ€• Radiotherapy and Oncology, 2016, 118, 35-42.	0.3	286
146	Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-House Analysis System. Technology in Cancer Research and Treatment, 2016, 15, 348-354.	0.8	4
147	Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific Î±/Î²-Values for Patients with Non-Resectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0164473.	1.1	5
148	Mobile Apps in Oncology: A Survey on Health Care Professionalsâ€™ Attitude Toward Telemedicine, mHealth, and Oncological Apps. Journal of Medical Internet Research, 2016, 18, e312.	2.1	83
149	The Interdisciplinary Management of Brain Metastases. Deutsches Ärzteblatt International, 2016, 113, 415-21.	0.6	17
150	Data management, documentation and analysis systems in radiation oncology: a multi-institutional survey. Radiation Oncology, 2015, 10, 230.	1.2	8
151	Study of Preoperative Radiotherapy for Sarcomas of the Extremities with Intensity-Modulation, Image-Guidance and Small Safety-margins (PREMISS). BMC Cancer, 2015, 15, 904.	1.1	16
152	Dosimetric impact of different CT datasets for stereotactic treatment planning using 3D conformal radiotherapy or volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 249.	1.2	13
153	Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) â€“ the ESMERALDA trial. Radiation Oncology, 2015, 10, 143.	1.2	11
154	Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiation Oncology, 2015, 10, 237.	1.2	15
155	Outcomes of Patients with Squamous Cell Carcinoma of Esophagus who did not receive Surgical Resection after Neoadjuvant Radiochemotherapy. Tumori, 2015, 101, 263-267.	0.6	2
156	The Prognostic Value of Irradiated Lung Volumes on the Prediction of Intra-/ Post-Operative Mortality in Patients after Neoadjuvant Radiochemotherapy for Esophageal Cancer. A Retrospective Multicenter Study.. Journal of Cancer, 2015, 6, 254-260.	1.2	2
157	Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Frontiers in Immunology, 2015, 6, 556.	2.2	67
158	Paving the Road for Modern Particle Therapyâ€‰â€“â€‰What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?. Frontiers in Oncology, 2015, 5, 262.	1.3	19
159	Radiation-induced motility alterations in medulloblastoma cells. Journal of Radiation Research, 2015, 56, 430-436.	0.8	14
160	Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) â€“ From Preclinical Studies to a Clinical Phase II Trial. Frontiers in Immunology, 2015, 6, 162.	2.2	87
161	Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma. BMC Cancer, 2015, 15, 558.	1.1	31
162	Implications of free breathing motion assessed by 4D-computed tomography on the delivered dose in radiotherapy for esophageal cancer. Medical Dosimetry, 2015, 40, 378-382.	0.4	2

#	Article	IF	Citations
163	Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results. Annals of Surgical Oncology, 2015, 22, 2068-2074.	0.7	50
164	Integrin-based meningioma cell migration is promoted by photon but not by carbon-ion irradiation. Strahlentherapie Und Onkologie, 2015, 191, 347-355.	1.0	5
165	Corrigendum to â€œHPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)â€•[Radiother. Oncol. 113 (2014) 317â€“323]. Radiotherapy and Oncology, 2015, 114, 419.	0.3	0
166	Treatment tolerance of particle therapy in pediatric patients. Acta OncolÃ³gica, 2015, 54, 1049-1055.	0.8	22
167	Clinical implementation and range evaluation of in vivo PET dosimetry for particle irradiation in patients with primary glioma. Radiotherapy and Oncology, 2015, 115, 179-185.	0.3	43
168	Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbeck's Archives of Surgery, 2015, 400, 749-756.	0.8	2
169	Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World Journal of Surgical Oncology, 2015, 13, 149.	0.8	3
170	Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas â€“ Pooled results from 3 large German centers. Radiotherapy and Oncology, 2015, 114, 378-383.	0.3	83
171	Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncology, 2015, 17, 312-319.	0.6	64
172	The importance of surrounding tissues and window settings for contouring of moving targets. Strahlentherapie Und Onkologie, 2015, 191, 750-756.	1.0	3
173	Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. BMC Cancer, 2015, 15, 537.	1.1	10
174	Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus. Strahlentherapie Und Onkologie, 2015, 191, 153-160.	1.0	13
175	The Relative Biological Effectiveness for Carbon and Oxygen Ion Beams Using the Raster-Scanning Technique in Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2014, 9, e113591.	1.1	34
176	Radiotherapy in Patients with Vestibular Schwannoma and Neurofibromatosis Type 2: Clinical Results and Review of the Literature. Tumori, 2014, 100, 189-194.	0.6	14
177	Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013". Radiation Oncology, 2014, 9, 224.	1.2	1
178	Re-irradiation in the treatment of patients with cerebral metastases of solid tumors: retrospective analysis. Radiation Oncology, 2014, 9, 4.	1.2	35
179	Residual motion mitigation in scanned carbon ion beam therapy of liver tumors using enlarged pencil beam overlap. Radiotherapy and Oncology, 2014, 113, 290-295.	0.3	31
180	Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology, 2014, 16, 434-440.	0.6	120

#	Article	IF	Citations
181	Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiation Oncology, 2014, 9, 203.	1.2	60
182	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
183	Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Computer Methods and Programs in Biomedicine, 2014, 114, 206-217.	2.6	39
184	Time evaluation of image-guided radiotherapy in patients with spinal bone metastases. Strahlentherapie Und Onkologie, 2014, 190, 287-292.	1.0	6
185	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Journal of Neuro-Oncology, 2014, 117, 85-92.	1.4	11
186	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research, 2014, 20, 6304-6313.	3.2	111
187	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. Journal of Neurochemistry, 2014, 131, 251-264.	2.1	47
188	Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort. Radiation Oncology, 2014, 9, 128.	1.2	24
189	Glioblastoma Recurrence Patterns After Radiation Therapy With Regard to the Subventricular Zone. International Journal of Radiation Oncology Biology Physics, 2014, 90, 886-893.	0.4	104
190	Photon-induced cell migration and integrin expression promoted by DNA integration of HPV16 genome. Strahlentherapie Und Onkologie, 2014, 190, 944-949.	1.0	1
191	Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. European Journal of Medical Research, 2014, 19, 24.	0.9	12
192	Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2014, 21, 2801-2807.	0.7	31
193	A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?. Radiation Oncology, 2014, 9, 95.	1.2	115
194	Four-Dimensional Patient Dose Reconstruction for Scanned Ion Beam Therapy of Moving Liver Tumors. International Journal of Radiation Oncology Biology Physics, 2014, 89, 175-181.	0.4	43
195	Clinical response and tumor control based on longâ€term followâ€up and patientâ€reported outcomes in patients with chemodectomas of the skull base and head and neck region treated with highly conformal radiation therapy. Head and Neck, 2014, 36, 22-27.	0.9	23
196	Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2006-2006.	0.8	2
197	Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature. Tumori, 2014, 100, 189-94.	0.6	13
198	Evaluation of chemoradiotherapy with carbon ions and the influence of p53 mutational status in the colorectal carcinoma cell line HCT 116. Tumori, 2014, 100, 675-84.	0.6	6

#	Article	IF	Citations
199	Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution. Radiation Oncology, 2013, 8, 175.	1.2	41
200	Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiation Oncology, 2013, 8, 161.	1.2	45
201	Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanced pancreatic cancer. Radiation Oncology, 2013, 8, 138.	1.2	10
202	Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma â€“ feasibility and clinical response. Radiation Oncology, 2013, 8, 59.	1.2	70
203	Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiation Oncology, 2013, 8, 27.	1.2	46
204	Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiation Oncology, 2013, 8, 18.	1.2	26
205	Hearing preservation after radiotherapy for vestibular schwannomas is comparable to hearing deterioration in healthy adults and is accompanied by local tumor control and a highly preserved quality of life (QOL) as patientsâ€™ self-reported outcome. Radiotherapy and Oncology, 2013, 106, 175-180.	0.3	40
206	Radiation Therapy for the Treatment of Diffuse Low-Grade Gliomas. , 2013, , 423-434.		0
207	Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Strahlentherapie Und Onkologie, 2013, 189, 738-744.	1.0	37
208	Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlentherapie Und Onkologie, 2013, 189, 745-752.	1.0	37
209	Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines â€“ does scheduling matter?. International Journal of Radiation Biology, 2013, 89, 692-697.	1.0	15
210	Electrophysiological Monitoring in Patients With Tumors of the Skull Base Treated by Carbon-12 Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 978-983.	0.4	4
211	Clinical Controversies: Proton Radiation Therapy for Brain and Skull Base Tumors. Seminars in Radiation Oncology, 2013, 23, 120-126.	1.0	32
212	Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer, 2013, 13, 419.	1.1	22
213	Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro. Radiation Oncology, 2013, 8, 260.	1.2	46
214	Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanomaâ€“a randomized trial. Radiation Oncology, 2013, 8, 234.	1.2	13
215	Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiotherapy and Oncology, 2013, 109, 487-492.	0.3	74
216	Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis. Radiotherapy and Oncology, 2013, 108, 132-135.	0.3	42

#	Article	IF	Citations
217	Skull base meningiomas: Long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiotherapy and Oncology, 2013, 106, 186-191.	0.3	108
218	Chemoradiotherapy for locally advanced pancreatic cancer. Lancet Oncology, The, 2013, 14, 269-270.	5.1	9
219	Implementation and initial clinical experience of offline PET/CT-based verification of scanned carbon ion treatment. Radiotherapy and Oncology, 2013, 107, 218-226.	0.3	100
220	Advanced-stage pancreatic cancer: therapy options. Nature Reviews Clinical Oncology, 2013, 10, 323-333.	12.5	183
221	The stability of osseous metastases of the spine in lung cancer â€“ a retrospective analysis of 338 cases. Radiation Oncology, 2013, 8, 200.	1.2	35
222	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology, 2013, 15, 1405-1412.	0.6	53
223	Analysis of inter- and intrafraction accuracy of a commercial thermoplastic mask system used for image-guided particle radiation therapy. Journal of Radiation Research, 2013, 54, i69-i76.	0.8	13
224	Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta OncolÃ³gica, 2013, 52, 1504-1509.	0.8	55
225	Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and ⁶⁸Ga-DOTATOC-PET. Acta OncolÃ³gica, 2013, 52, 514-520.	0.8	68
226	Treatment with heavy charged particles: Systematic review of clinical data and current clinical (comparative) trials. Acta OncolÃ³gica, 2013, 52, 1272-1286.	0.8	33
227	Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. Journal of Radiation Research, 2013, 54, i61-i68.	0.8	79
228	Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. Journal of Radiation Research, 2013, 54, i6-i12.	0.8	10
229	In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. Journal of Radiation Research, 2013, 54, i113-i119.	0.8	36
230	Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta OncolÃ³gica, 2013, 52, 147-152.	0.8	98
231	Current status of 4D offline PET-based treatment verification at the Heidelberg Ion-Beam Therapy Center. , 2013, , .		1
232	An evaluation system for electronic retrospective analyses in radiation oncology: implemented exemplarily for pancreatic cancer. Proceedings of SPIE, 2013, , .	0.8	0
233	Optimizing Contrast-Enhanced Magnetic Resonance Imaging Characterization of Brain Metastases. Neurosurgery, 2013, 72, 691-701.	0.6	26
234	Web-based documentation system with exchange of DICOM RT for multicenter clinical studies in particle therapy. , 2012, , .		1

#	Article	IF	Citations
235	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 707-715.	5.1	980
236	Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection. Strahlentherapie Und Onkologie, 2012, 188, 795-801.	1.0	30
237	Carbon Ion Irradiation Inhibits Glioma Cell Migration Through Downregulation of Integrin Expression. International Journal of Radiation Oncology Biology Physics, 2012, 83, 394-399.	0.4	42
238	Long-Term Outcome After Radiotherapy in Patients With Atypical and Malignant Meningiomasâ€"Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 859-864.	0.4	128
239	Monitoring of patients treated with particle therapy using positron-emission-tomography (PET): the MIRANDA study. BMC Cancer, 2012, 12, 133.	1.1	31
240	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer, 2012, 12, 137.	1.1	46
241	Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1409-1415.	3.3	139
242	State-of-the-art treatment alternatives for base of skull meningiomas: complementing and controversial indications for neurosurgery, stereotactic and robotic based radiosurgery or modern fractionated radiation techniques. Radiation Oncology, 2012, 7, 226.	1.2	68
243	First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiation Oncology, 2012, 7, 189.	1.2	48
244	Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiation Oncology, 2012, 7, 170.	1.2	44
245	Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiation Oncology, 2012, 7, 130.	1.2	34
246	Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. Radiation Oncology, 2012, 7, 115.	1.2	11
247	Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiation Oncology, 2012, 7, 44.	1.2	37
248	Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts. Radiation Oncology, 2012, 7, 41.	1.2	46
249	Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiation Oncology, 2012, 7, 28.	1.2	86
250	Early Treatment Response of a Rare Papillary Tumor of the Pineal Region after Primary Proton-Beam Therapy using the Raster-Scanning Technique at HIT. Tumori, 2012, 98, e122-e125.	0.6	3
251	In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells. Radiation Oncology, 2012, 7, 9.	1.2	50
252	p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 187-199.	2.2	25

#	Article	IF	Citations
253	Future Directions in Ion Beam Therapy. Biological and Medical Physics Series, 2012, , 703-717.	0.3	0
254	Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions. Biological and Medical Physics Series, 2012, , 179-192.	0.3	0
255	Early treatment response of a rare papillary tumor of the pineal region after primary proton-beam therapy using the raster-scanning technique at HIT. Tumori, 2012, 98, 122e-125e.	0.6	1
256	Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiotherapy and Oncology, 2011, 98, 63-67.	0.3	64
257	Improved Correlation of the Neuropathologic Classification According to Adapted World Health Organization Classification and Outcome After Radiotherapy in Patients With Atypical and Anaplastic Meningiomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1415-1421.	0.4	59
258	Assessment of Early Toxicity and Response in Patients Treated With Proton and Carbon Ion Therapy at the Heidelberg Ion Therapy Center Using the Raster Scanning Technique. International Journal of Radiation Oncology Biology Physics, 2011, 81, e793-e801.	0.4	39
259	Outcome and Prognostic Factors of Radiation Therapy for Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e7-e13.	0.4	47
260	Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: An analysis of survival and treatment efficacy. Tumori, 2011, 97, 609-613.	0.6	23
261	Helical tomotherapy for meningiomas of the skull base and in paraspinal regions with complex anatomy and/or multiple lesions. Tumori, 2011, 97, 484-491.	0.6	8
262	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. BMC Cancer, 2011, 11, 67.	1.1	37
263	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. Radiation Oncology, 2011, 6, 115.	1.2	99
264	Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiation Oncology, 2011, 6, 117.	1.2	35
265	Targeting Î±Î½Î²3 and Î±Î½Î²5 inhibits photon-induced hypermigration of malignant glioma cells. Radiation Oncology, 2011, 6, 132.	1.2	28
266	Helical tomotherapy for meningiomas of the skull base and in paraspinal regions with complex anatomy and/or multiple lesions. Tumori, 2011, 97, 484-91.	0.6	6
267	Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. Tumori, 2011, 97, 609-13.	0.6	18
268	Biopsy Targeting Gliomas. Investigative Radiology, 2010, 45, 755-768.	3.5	57
269	Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. BMC Cancer, 2010, 10, 450.	1.1	16
270	Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial. BMC Cancer, 2010, 10, 478.	1.1	83

#	Article	IF	Citations
271	Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial. BMC Cancer, 2010, 10, 533.	1.1	75
272	Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer, 2010, 10, 606.	1.1	56
273	Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer, 2010, 10, 607.	1.1	70
274	Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial. BMC Cancer, 2010, 10, 615.	1.1	48
275	Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer, 2010, 10, 96.	1.1	56
276	Differences in Clinical Results After LINAC-Based Single-Dose Radiosurgery Versus Fractionated Stereotactic Radiotherapy for Patients With Vestibular Schwannomas. International Journal of Radiation Oncology Biology Physics, 2010, 76, 193-200.	0.4	136
277	Carbon ion radiation therapy for high-risk meningiomas. Radiotherapy and Oncology, 2010, 95, 54-59.	0.3	75
278	Particle therapy at the Heidelberg Ion Therapy Center (HIT) â€“ Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiotherapy and Oncology, 2010, 95, 41-44.	0.3	119
279	Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta OncolÃ³gica, 2010, 49, 1132-1140.	0.8	93
280	Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells. Clinical Cancer Research, 2010, 16, 2715-2728.	3.2	279
281	Long-Term Outcome of Postoperative Irradiation in Patients with Newly Diagnosed WHO Grade III Anaplastic Gliomas. Tumori, 2009, 95, 317-324.	0.6	10
282	Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer, 2009, 115, 1348-1355.	2.0	73
283	Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. International Journal of Radiation Biology, 2009, 85, 126-137.	1.0	71
284	Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: Results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. Radiotherapy and Oncology, 2009, 91, 60-66.	0.3	20
285	Radiation Therapy. Recent Results in Cancer Research, 2009, 171, 125-140.	1.8	8
286	Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori, 2009, 95, 317-24.	0.6	6
287	Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. Journal of Neuro-Oncology, 2008, 89, 205-210.	1.4	81
288	In Reply to Dr. Jalali. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1622-1623.	0.4	0

#	Article	IF	Citations
289	Postoperative Treatment of Primary Glioblastoma Multiforme With Radiation and Concomitant Temozolomide in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2008, 70, 987-992.	0.4	138
290	Radiochemotherapy in Patients With Primary Glioblastoma Comparing Two Temozolomide Dose Regimens. International Journal of Radiation Oncology Biology Physics, 2008, 71, 999-1005.	0.4	41
291	Influence of Radiotherapy Treatment Concept on the Outcome of Patients With Localized Ependymomas. International Journal of Radiation Oncology Biology Physics, 2008, 71, 972-978.	0.4	19
292	Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiotherapy and Oncology, 2008, 88, 177-182.	0.3	27
293	On the cost-effectiveness of Carbon ion radiation therapy for skull base chordoma. Radiotherapy and Oncology, 2007, 83, 133-138.	0.3	36
294	Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer, 2007, 109, 2308-2314.	2.0	106
295	3D radial projection technique with ultrashort echo times for sodium MRI: Clinical applications in human brain and skeletal muscle. Magnetic Resonance in Medicine, 2007, 57, 74-81.	1.9	166
296	Carbon ion radiotherapy of skull base chondrosarcomas. International Journal of Radiation Oncology Biology Physics, 2007, 67, 171-177.	0.4	177
297	Effectiveness of Carbon Ion Radiotherapy in the Treatment of Skull-Base Chordomas. International Journal of Radiation Oncology Biology Physics, 2007, 68, 449-457.	0.4	276
298	In Vitro Responsiveness of Glioma Cell Lines to Multimodality Treatment With Radiotherapy, Temozolomide, and Epidermal Growth Factor Receptor Inhibition With Cetuximab. International Journal of Radiation Oncology Biology Physics, 2007, 68, 873-882.	0.4	34
299	Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer, 2007, 7, 167.	1.1	78
300	Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer, 2007, 7, 177.	1.1	45
301	Local High-Dose Radiotherapy and Sparing of Normal Tissue Using Intensity-Modulated Radiotherapy (IMRT) for Mucosal Melanoma of the Nasal Cavity and Paranasal Sinuses. Strahlentherapie Und Onkologie, 2007, 183, 63-68.	1.0	41
302	Moderne Radioonkologie. , 2007, , 93-107.		0
303	Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes. Radiation Oncology, 2006, 1, 23.	1.2	45
304	Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1341-1347.	0.4	103
305	Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) â€“ phase I/II trial: study protocol. BMC Cancer, 2006, 6, 133.	1.1	78
306	Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT). BMC Cancer, 2006, 6, 222.	1.1	32

#	Article	IF	Citations
307	Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. International Journal of Radiation Oncology Biology Physics, 2005, 62, 797-802.	0.4	21
308	Fractionated stereotactic radiotherapy of optic pathway gliomas: Tolerance and long-term outcome. International Journal of Radiation Oncology Biology Physics, 2005, 62, 814-819.	0.4	103
309	Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): Long-term results in 106 patients treated in a single institution. International Journal of Radiation Oncology Biology Physics, 2005, 63, 75-81.	0.4	183
310	Stereotactic radiosurgery (SRS). Cancer, 2005, 104, 2168-2173.	2.0	194
311	Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer, 2005, 104, 2457-2465.	2.0	73
312	Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma Multiforme. Strahlentherapie Und Onkologie, 2005, 181, 372-377.	1.0	75
313	Reirradiation of Recurrent WHO Grade III Astrocytomas Using Fractionated Stereotactic Radiotherapy (FSRT). Strahlentherapie Und Onkologie, 2005, 181, 768-773.	1.0	33
314	Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution. Journal of Clinical Oncology, 2005, 23, 8863-8869.	0.8	288
315	Treatment of Cerebral Metastases from Breast Cancer with Stereotactic Radiosurgery. Strahlentherapie Und Onkologie, 2004, 180, 590-596.	1.0	84
316	Light ion facility projects in Europe: methodological aspects for the calculation of the treatment cost per protocol. Radiotherapy and Oncology, 2004, 73, S183-S185.	0.3	8
317	Reduction of endogenous TGF-Î² does not affect phenotypic development of sympathoadrenal progenitors into adrenal chromaffin cells. Mechanisms of Development, 2001, 109, 295-302.	1.7	9
318	Reduction of endogenous TGF-? increases proliferation of developing adrenal chromaffin cells in vivo. , 2000, 59, 379-383.		21
319	Neoadjuvant Radiation in High-Grade Soft-Tissue Sarcomas. American Journal of Surgical Pathology, 0, Publish Ahead of Print, .	2.1	3
320	Subclinical Left Ventricular Dysfunction Detected by Speckle-Tracking Echocardiography in Breast Cancer Patients Treated With Radiation Therapy: A Six-Month Follow-Up Analysis (MEDIRAD EARLYâ€HEART) Tj ETQq0 0 0 rgBT /Overloc		